In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeking New Opportunities For Traditional Chinese Medicine

This article was originally published in PharmAsia News

Executive Summary

A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.

You may also be interested in...



China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market

SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market

Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition

Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys

The Coartem Story: Novartis Workers In NY Feel Uplift In Battling Malaria

On New Year's Eve in 2005, the operators of Novartis' plant in Suffern, N.Y. were jubilant. The facility had just manufactured its 20 millionth treatment of Coartem (artemether/lumefantrine)

Topics

Related Companies

UsernamePublicRestriction

Register

SC085001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel